

CALL FOR PROPOSALS 2025

Japan-Switzerland

AMED-SNSF ASPIRE

Joint-Call for Proposals

A maximum of 3 joint projects will be funded.

Submission deadline: July 1st, 2025

☞ for Japan-based applicants

- <https://www.e-rad.go.jp/>

☞ for Swiss-based applicants

[Strategic Japanese-Swiss Science and Technology Programme](#)

1. CONTEXT AND OBJECTIVE OF THE CALL

Japan and Switzerland invite proposals for research focusing on age-related changes in the immune system, particularly age-related inflammation (inflammaging). The aim of this joint research is to elucidate the mechanisms by which a reduced immune response due to ageing increases the risk of infectious and inflammatory diseases. Bringing together our efforts across borders is a promising strategy to enhance our impact. As such, the Japanese Agency for Medical Research and Development (AMED) and the Swiss National Science Foundation (SNSF) are launching a call for proposals to support exceptional collaborative projects between Japan-based and Swiss-based researchers in the field of inflammaging related health research.

This joint initiative aims at delivering joint research funding for internationally competitive and innovative collaborative projects between researchers from Japan and Switzerland to promote transnational expertise synergy and mutualization. AMED will support this activity under the ASPIRE (Adopting Sustainable Partnerships for Innovative Research Ecosystem) fund.

These collaborative research projects will also allow the establishment and maintenance of sustainable partnerships between Japan and Switzerland, by supporting researcher's mobility between the 2 countries. **In fact, it is required that at least 33% of the total requested Japanese funding should be used for the purpose of building and expanding networks with the partner country and promoting mobility. The Swiss partners are encouraged to match this amount in their budget allocation.**

The objectives of the AMED-SNSF joint funding call are to:

- Support projects that are original in their subject and approaches, ambitious and feasible in their objectives;
- Support collaborative projects within new or pre-existing partnerships to foster sustainable research links between Japan and Switzerland;
- Promote exchange of scientists, knowledge and methodology between the two countries;
- Allow mutualization/access to facilities, resources and equipment available in the two countries;
- Foster cross-disciplinary research;
- Stimulate research on emerging and innovative topics to open new perspectives in inflammaging.

2. SCOPE OF THE CALL

Call Topic: Mechanisms and Modulation of Inflammaging

This AMED-SNSF joint call focuses on investigating the causes and biological mechanisms of chronic, low-grade inflammation associated with ageing, commonly referred to as “inflammaging”. The collaboration seeks to elucidate how cellular, molecular and systemic factors contribute to inflammaging and to develop targeted interventions to mitigate its impact on age-related diseases. By fostering interdisciplinary collaborations, the project aims to identify novel therapeutic pathways to enhance healthy life expectancy and improve the quality of life of ageing populations.

This joint call is open to all areas of basic research and scientific fields involved in the investigation of inflammaging-related health research. It aims to support cutting-edge research projects that address challenges in inflammaging-related health research, with the goal of expanding our understanding of the biological mechanisms underlying inflammaging.

The call seeks to bridge cellular and molecular research with systemic health outcomes. The collaboration encourages comprehensive approaches to alleviating inflammaging by targeting specific pathways, including miRNA regulation, inflammasome activation, immune cell ageing and gut microbiota modulation. These approaches are expected to provide valuable insights into managing chronic inflammation to prevent or delay the onset of multiple age-related diseases, thereby improving life expectancy and quality of life.

3. ELIGIBILITY CRITERIA

3.1 Teams' eligibility

The research project must be joint research by a research team comprising Japan-based and Swiss-based researchers.

The proposal must be jointly prepared by two applicants; one from the Japan-based team and one from the Swiss-based team.

The applicants are subjected to eligibility criteria of their respective funding agency.

Eligibility criteria in Japan: Please refer to “[AMED Call Supplemental Guidance](#)” for Japan-based teams.

Eligibility criteria in Switzerland: Applicants requesting funding must meet the eligibility requirements of the SNSF. The [SNSF Funding Regulations](#), the [General implementation regulations](#) and the [Regulations on Project Funding](#) are applicable or applicable mutatis mutandis where not stated otherwise. All applicants may only submit one proposal per call and must be based in Switzerland. Project partners as described in Article 11, Paragraph 2 of the [SNSF Funding Regulations](#) are not entitled to receive funds from the SNSF if their affiliated institution is located in Japan. Applicants can submit a proposal for a JRP under the present call even if they hold or have applied for

another SNSF grant. Moreover, grantees may submit proposals to all SNSF funding schemes during the funding period of a JRP. In either case, substantial thematic overlaps must be avoided, and applicants must be in a position to make substantial contributions to each of the research projects (cf. Article 17 of the [SNSF Funding Regulations](#)). Please note that the present call is not in conflict with the restrictions applicable to the SNSF's national project funding in accordance with Article 13 of the [Regulations on Project Funding](#).

Non-compliance with the eligibility rules will lead to the rejection of the entire proposal without further review:

- Each unique project must involve at least two applicants, one Japan-based and one Swiss-based, responsible for the research management and for all the communications with the respective funding agency.
- Only collaborative Japan-Switzerland projects will be funded.
- Proposals will be submitted by each corresponding applicant individually. The Japan-based applicant will submit the project to AMED (which is strictly identical to the project submitted to SNSF) and the Swiss-based applicant will submit the same project to SNSF. The teams will be funded by the funding agency from their country (AMED for Japan-based teams and SNSF for Swiss-based teams) and are therefore subject to respective eligibility rules.
- Researches not eligible for funding by AMED or SNSF (e.g. based outside Japan and Switzerland or not fundable according to the regulations of AMED or SNSF) may participate in projects as long as they secure their own funding for the project.
- Researchers from third countries, who make a partial contribution to the project without being responsible for the project can be included as project partners (in the Swiss part), but costs must correspond to no more than 20% of the overall Swiss budget. However, please note that researchers who are located in Japan cannot be included as project partners.
- Japanese applicants should refer to the "[AMED Call Supplemental Guidance](#)" containing all the specific AMED eligibility criteria and should contact their respective funding agency contact points for additional clarification.

4. PROJECT DURATION

The duration of the projects should be of five (5) years for Japan-based researchers and four (4) years for Swiss-based researchers.

5. FINANCIAL AND LEGAL ISSUES

5.1 Available Funding

This joint call for proposals aims at funding up to three Japanese-Swiss collaborative projects. AMED will support up to 345 million JPY direct cost for five (5) years (capped maximum value of 115 million JPY per project) and SNSF will support the Swiss components of the projects for up to CHF 625'000 per project (the total budget on the Swiss side is CHF 1'875'000). It is strongly recommended that this collaboration is mutually beneficial for Japan-based and Swiss-based researchers and that the research cost is comparable.

5.2 Funding model and funding details

Funding will be made available by AMED and SNSF according to their specific regulations, AMED will fund Japan-based teams and SNSF will fund Swiss-based teams.

Funding is granted for five (5) years **for Japan-based researchers and four (4) years for Swiss-based researchers**. Please refer to the "[AMED Call Supplemental Guidance](#)" for Japan-based applicants and "Guidelines for Swiss-based applicants" (see Annex) for the funding modalities and specific derogatory conditions.

Japan-based and Swiss-based PIs will get a separate funding contract/letter of grant from AMED or SNSF. In Switzerland, the decision letters will not be subject to appeal.

Depending on the time needed for the administration of granting funds to the respective national research groups, individual projects of a research team are expected to start by December 2025 on the Japanese side. The Swiss side has until March 2026 to begin working on the project. Project start dates are tentative and subject to change.

5.3 Grant payment scheme

Please refer to the “Administrative Instruction” for Japan-based PIs which can be found on the AMED website. The payments on the Swiss side will follow the usual SNSF procedure. In principle, the budgets for JRPs are transferred in annual instalments to the affiliated institution of the corresponding applicant in Switzerland at the beginning of a project year.

5.4 Funding for international partnership and mobility activities

At least 33% of the total eligible cost should be dedicated to international and mobility activities with the aim of building and extending a network between the Japan-based and the Swiss-based research community. The Japan-based PI will consult with the Swiss-based PI and coordinate to ensure that the mobility costs are at least 33% of the total costs of the Japanese budget. The Swiss side is encouraged to follow this approach. If the total mobility costs for both the Japanese and Swiss applicants do not reach 33% of the total budget for both countries, the Japanese applicant must cover the Swiss applicant's mobility costs to meet the 33% requirement. These expenses can include the costs of organizing workshops/seminars etc, travel of researchers to the partner country and related expenses, personnel costs for staff involved in travel and exchanges, and research and other costs related to hosting researchers from the partner country. Please see table below for more detail of the costs chargeable in this 33%:

Main Item	Definition
Research costs (equipment/supplies) when hosting researchers	Research facilities/equipment/prototypes, software (ready-made goods), purchasing costs for reagents/materials/consumables for use in research
Travel costs for personal exchanges and joint meetings	Travel costs of Swiss research participants, travel costs for invited participants such as external experts
Personnel costs/ services costs for expatriates	Personnel costs for those traveling: personnel costs for researchers, etc., employed to conduct the relevant contracted research (including personnel costs for PIs) and related costs e.g. interpretation/translation
Other costs for international partnership and mobility activities	Costs for implementing the relevant contracted research other than the above. Examples: conference costs, equipment leasing costs, Equipment repair costs and subcontract costs.

Please refer to the “[AMED Call Supplemental Guidance](#)” for Japan-based applicants which can be found on the AMED website.

5.5 Collaboration research agreement, ownership of intellectual property rights, ethical issues

In order to ensure a proper conduct of the project activities, a Collaboration Research Agreement (CRA) must be signed between the partners. The research team is strongly encouraged to sign this CRA before the official project start date. The CRA must be signed no later than six (6) months after the official project start date. If CRA cannot be signed within 6 months, the PI should consult the Secretariat (see annex). The CRA must address the following issues: governance structure and decision-making process, responsibilities between the partners and subsequent liability, reporting, ownership and use of research results, intellectual property rights (IPR), publications, confidentiality.

Results and new IPR resulting from projects funded through the AMED-SNSF joint call will be owned by the relevant organizations or persons according to international/national/regional/institutional rules on IPR. If several participants have jointly carried out work generating new IPR, they shall agree amongst themselves (CRA) as to the allocation of ownership of IPR, taking into account their contributions to the creation of those IPR and national guidelines on IPR issues.

The results of the research project and IPR created should be disseminated and made available for a broad and most beneficial use according to the objective of the call.

AMED and SNSF shall have the right to use documents, information and results submitted by the research partners and/or to use the information and results for their own purposes, provided that the owners' rights are kept.

Any ethical issues, arising for instance if a research project includes a study on patient samples, should be addressed at the proposal submission stage, and subsequent authorisation presented at the latest, upon request by the funding organisations, before the process of grant negotiation.

5.6 Confidentiality of proposals

Proposals and any relating information shall be kept confidential by the evaluation committee members. Proposals shall not be used for any purpose other than the evaluation and subsequent monitoring of the funded projects.

Proposals will be required to include a publishable summary, which will clearly identify the main goals of the project. If a proposal is funded, this information as well as the name of the researcher, the funds accorded to the project, and the start- and end date of the project will be published on AMED and SNSF website. All other project details shall remain strictly confidential.

6. SUBMISSION OF JOINT PROPOSALS

The AMED-SNSF joint call will be implemented through a one stage submission procedure. The co-developed proposals between Japan and Swiss-based teams should be written in English and submitted to both AMED and SNSF, to AMED through [e-rad](#) by the Japan-based PI and to SNSF through "[mySNF](#)" by the Swiss-based PI.

In preparing the proposals, applicants must strictly follow the rules described in this call text and comply with AMED and SNSF rules, by referring to "[AMED Call Supplemental Guidance](#)" found on AMED website for applicants based in Japan and to the "Guideline

for Swiss-based applicants” (see annex) for Swiss-based researchers. Applicants can reach their contact points for specific questions.

The proposals must be submitted to the electronic submission system no later than **July 1st, 2025 at 17h00 (JST) for Japan-based teams/ and July 1st, 2025 at 17h00 (Central European Summer Time, CEST) for Swiss-based teams**. Please note that failure to submit a valid proposal to both AMED and SNSF by the respective deadline will invalidate both submissions.

The decision on the results of the proposal evaluation meeting will be communicated to all (successful and unsuccessful) applicants in November 2025. Applicants will receive a summary of the proposal evaluation conclusions.

7. TIMELINE OF THE CALL

January 2025	Pre-announcement of the call
April 2025	Publication of the call and opening of the submission system for proposals
July 1st, 2025 at 17h00 (CEST) July 1st, 2025 at 17h00 (JST)	Deadline for proposal submission
November 2025 (TBD)	Communication of the funding decisions to the applicants
December 2025 (TBD)	Expected project start (also subject to national procedures) in Japan
March 2026 (TBD)	Expected project start in Switzerland

8. ELIGIBILITY CHECK

All proposals will be examined to ensure that they meet the call's formal criteria (date of submission, countries representation, inclusion of all necessary information in English, adherence to the proposal forms).

After completion of the eligibility check, AMED and SNSF will reject proposals that are not considered eligible without further review. Applicants having submitted non-eligible proposals will be informed by AMED and SNSF respectively.

If the proposal is incomplete, or if the proposal is submitted only to AMED or SNSF, AMED and SNSF will not accept the proposal.

9. EVALUATION COMMITTEE

The Evaluation Committee will manage the evaluation of proposals and the final selection of research projects for funding, with the support of the Joint Call Secretariat (AMED and SNSF project and administrative officers).

Based on the ranking list established by the Evaluation Committee, AMED will take the final decision on the proposals to be funded and SNSF will follow AMED's decision.

The Evaluation Committee is a panel of internationally recognized scientific experts in charge of the review and evaluation of submitted proposals.

10. EVALUATION CRITERIA

Proposals will be assessed according to the following criteria:

Scientific quality and vision of the project:

- a. Excellence regarding the state of the science/the art;
- b. Relevance of the project with regard to the scope of the project;
- c. Positioning of the project at the national and international level;
- d. Relevance, novelty and originality of the project;
- e. Clarity of the objectives and overall plan of the project.

Japan-Switzerland Research Partnership:

- a. Competitiveness and synergy of the Japan- Switzerland research collaboration in the field of basic inflammaging related research;
- b. Strength, sustainability and added value of the partnership;
- c. Clarity, appropriateness and feasibility of the governance arrangements and division of roles between Japan and Swiss-based research teams;
- d. Strategy to foster knowledge and methodology exchange between the partner teams;
- e. Plan for building and expanding the international collaboration in an equally beneficial manner to both Japan and Switzerland.

Principal Investigators and the research teams:

- a. Quality and experience of the PIs regarding the project objectives. Young PI are encouraged to take responsibility in the submitted project;
- b. Experience of the PI in international research communities and with co-investigators from foreign institution;
- c. Excellence of the associated teams participating in the project and their team heads;
- d. Quality of the research partnership, relevance to project objectives and ability to generate results: expertise, complementarity and/or multidisciplinary of the teams collaborating in the project.

Methodology and feasibility:

- a. Quality of the proposed methodology: design, feasibility and technological relevance;
- b. Technical resources: access to technological platforms, data processing centres, biological resource centres associated with clinical data, etc.;
- c. Compliance with ethical rules and regulations;
- d. Quality of the coordination between the partners (meetings plan, preparation of monitoring reports, communication, etc.);
- e. Appropriateness and justification of the time schedule proposed regarding the project objectives.

Support for early career researchers

- a. Appropriateness of plans for cultivating next-generation researchers;
- b. Promotion of international mobility for next-generation researchers;
- c. Experience of Principal Investigators in human resources development for young researchers.

Impact of the project:

- a. Scientific, technical and/or medical impact in both Japan and Switzerland.
- b. Innovation in both Japan and Switzerland;
- c. Potential impact of the project results on the scientific, industrial and company communities (intellectual property, economic and company potential, etc.) in both Japan and Switzerland (if relevant).
- d. Perpetuation of the joint research partnership and promotion of a Switzerland-Japan research network beyond completion of the project.

Financial feasibility:

- a. Suitability of human resources allocated to the project;
- b. Appropriateness and justification of requested funding according to the proposed work plan;
- c. Clarity of the breakdown and justification of the proposed international and mobility activities and costs;
- d. Planned budget to host human resources from overseas partner lab;
- e. Planned budget to allow mobility of human resources to overseas partner's lab;

11. REPORTING AND DISSEMINATION

The PIs will be asked to submit financial and/or progress/activity reports to AMED or SNSF, whether Japan-based or Swiss-based respectively.

AMED reporting: Please refer to the “Administrative Instruction” for Japan-based PIs which can be found on the AMED website for details concerning the procedure in Japan).

SNSF reporting: The main applicant in Switzerland is responsible for the reporting to the SNSF. Standard SNSF regulations apply for both the financial and the scientific reports.

PIs in Japan and in Switzerland should submit the final report to AMED and SNSF respectively after completion of the period of international collaborative research. The submission should be made to AMED and SNSF within the timeframe specified by AMED and SNSF after the end of the grant. The report includes a general summary (the report format will be notified until the completion of the project) compiled jointly by both the Japan-based and the Swiss-based PIs. The PIs shall inform AMED and SNSF of serious difficulties in the conduct of the research project. AMED and SNSF will decide upon the proper actions to be taken.

Funding recipients must ensure that all results (publications, etc.) arising from the project include a proper acknowledgement that the project is collectively supported by AMED and SNSF under the framework of the AMED-SNSF joint call initiative.

12. Joint Call Secretariat contact

AMED contacts for Japan-based teams:

Sayaka Ohashi, Ph.D.

Department of International Strategy,

Japan Agency for Medical Research and Development

Website: Japan Agency for Medical Research and Development

E-mail: amed-aspire“AT”amed.go.jp (Replace “AT” with @)

SNSF contact for Swiss-based teams:

Dr. Isabelle Fellner

International Co-operation division

Swiss National Science Foundation

Wildhainweg 3,

P.O. Box CH-3001 Berne

Website: <http://www.snsf.ch>

E-mail: international@snf.ch

Telephone: +41 (0) 31 308 24 49

ANNEXES : Guide for applicants

Annex 1: Guidelines for Swiss-based applicants

Annex 2: [AMED Call Supplemental Guideline for Japan-based applicants \(in Japanese\)](#)

Annex 3: Application Form (“ASPIRE Japan-Swiss Joint Research 2025”)

Annex 1

Guidelines for Swiss-based Applicants: Eligibility, Funding, and Submission at the Swiss National Science Foundation

1 Eligibility

The Swiss applicants must meet the eligibility requirements of the SNSF. The [SNSF Funding Regulations](#), the [General implementation regulations](#) and the [Regulations on Project Funding](#) are applicable or applicable mutatis mutandis. Please note that private companies are not eligible for funding.

2 Funding Modalities

A maximum amount of CHF 625'000 is allocated per project for the Swiss side. Article 7 of the [Regulations on Project Funding](#) defines the eligible costs:

- salaries of scientific and technical staff in research projects within the scope of the salary ranges and rates prescribed by the SNSF;
- salaries of the Principal Investigators based in Switzerland cannot be covered;
- material costs that are directly related to the research work, namely material of enduring value, expendable items, field expenses, travel expenses, third-party charges, cost of computing time and data as well as of providing open access to research data;
- direct costs incurred through the use of research infrastructure linked to the research work;
- costs for the organisation of conferences and workshops in connection with the funded research;
- costs for national and international cooperation and networking activities carried out in connection with the funded research.

As of 1 April 2018, fees for open access publications are no longer eligible costs within SNSF grants and have to be requested separately via *mySNF*. The SNSF considers applications for Book Processing Charges (BPS) as of 1 April and for Article Processing Charges (APC) and Book Chapter Processing Charges (BCPC) as of 1 October 2018. Please visit www.snf.ch/oa for further information.

Swiss applicants may not apply for their own salaries.

Grants will be managed according to standard SNSF rules.

Researchers from third countries, who make a partial contribution to the project without being responsible for the project can be included as project partners (in the Swiss part), but costs must correspond to no more than **20% of the overall Swiss budget**. However, please note that researchers who are located in Japan cannot be included as project partners.

3 Submission

Swiss applicants must submit the application via the online submission system [mySNF](#). After logging in to mySNF, the correct funding instrument must be chosen (Programmes (national and international) > Bilateral Cooperation (Initiative of the State Secretary for Education, Research and Innovation) > Strategic Japanese-Swiss Science and Technology Programme (SJSSTP) > Strategic Japanese-Swiss Science and Technology Programme: AMED 2025

A Data Management Plan (DMP) is requested for approved grants according to the requirements issued by the SNSF. Funds can only be released once the DMP has been submitted. Missing or inaccurate statements in the DMP need to be added/revised at the latest before the release of the payment of the second instalment. A definitive and updated version of the DMP must be provided by the end of the project grant. For more details on the DMP format requirements and procedure see: [Data Management Plan \(DMP\) - Guidelines for re- searchers \(snf.ch\)](#)

For more information, please contact:

Isabelle Fellner Swiss National Science Foundation international@snf.ch +41 31 308 22 22

Application Form

[ASPIRE Japan-Swiss Joint Research 2025]

Note: When submitting please delete the examples in blue and the explanations in the green speech bubbles.

Title of proposed project	English	Study of XXX
	Japanese	〇〇に関する研究開発
Title of grant program		ASPIRE Japan-Swiss Joint Research 2025
Research period	Japan	Month Day, Year–Month Day, Year (5 years)
	Swiss	Month Day, Year–Month Day, Year (4 years)
Total amount of Research cost	Japan	Research cost over research period (X0,000 thousand yen)
	Swiss	Research cost over research period (XXX,000 CHF)
Human WGS analysis		<input type="checkbox"/> will be conducted <input type="checkbox"/> will not be conducted *Tick/check (☑) either of the above. If analysis will be conducted, submit the Human Whole Genome Sequence Analysis Protocol Form.
Principal Investigator (Japan)	Name	XXXX
	Sex	Male <input type="checkbox"/> Female <input type="checkbox"/> Other <input type="checkbox"/> Prefer not to respond <input type="checkbox"/>
	Month of birth (age)	Month Year (XX as of April 1, 2025)
	Affiliated institution (official name)	XX Corporation XX University
	Department/Division	Department of XXX, Faculty of XXX
	Position	XXX
	Information on the Principal Investigator (URL)	https://www.....
Research experience of the Principal Investigator (Japan) (main work experience and research content)		

Principal Investigator (Swiss)	Name	XXXX
	Sex	Male <input type="checkbox"/> Female <input type="checkbox"/> Other <input type="checkbox"/> Prefer not to respond <input type="checkbox"/>
	Month of birth (age)	Month Year (XX as of April 1, 2025)
	Affiliated institution (official name)	XX Corporation XX University
	Department/Division	Department of XXX, Faculty of XXX
	Position	XXX
	Information on the Principal Investigator (URL)	https://www.....
<p>Research experience of the Principal Investigator (Swiss)</p> <p>(main work experience and research content)</p>		

Summary (in Japanese and English)

■ Please enter the same Japanese abstract in e-Rad.

- Please provide an outline of the research proposal in no more than one A4 page in each of Japanese and English, including the following information.
- Background (what is the current situation and what is required)
- Purpose (the purpose of conducting this project in response to the background)
- Details of implementation (what methods will be used, how will the research be conducted, and how will the problem be solved)
- Expected results (goals to be achieved)
- The promotion of international joint research and international mobility activities

1. Research background and objectives

- **In A4 10 pages**, state specifically and clearly the objective of the research in a manner that will be easily understood by evaluators. Where necessary, add any diagrams or tables (words or numbers in the diagrams or tables are not included in the word limit).
- Please cite the information in the “Research Achievements” section appropriately, and clarify the relationship between the applicant's own achievements and the Research proposal.
- Please clearly distinguish between the background of the Research proposal (importance and necessity of the research), the applicant's achievements (facts), and the Research proposal.
- Please describe the following:
 - (1) Background of the Research proposal: To clarify the importance and necessity of the Research proposal, please include scientific and technological requirements, social demands, and trends in the field concerned and related fields, as appropriate.
 - (2) Purpose and Aim of the Research Proposal: Please describe the purpose and aims of the research and development proposal in detail, both for international joint research and for the promotion of international mobility activities.
 - (3) Details and expected results of the proposed research and development (International Joint Research): For international joint research, please provide specific details of the implementation of the Research proposal and the expected results (achievement targets). Please also explain the relationship between the research supported by the partner country's funding agency and this Research proposal.
 - (4) Details and Expected Results of the Research Proposal (International Mobility Activities): Please describe in detail the implementation details and expected results (achievement targets) of the Research proposal with respect to international mobility activities.
 - (5) Preparations for implementation of the Research proposal: Please describe in detail the history and results of the research conducted to date by the Principal Investigator (and, if necessary, by other members of the research item), as well as any preliminary findings and data that support the Research proposal, which will serve as the basis for promoting the research proposal.
 - (6) Novelty, originality, and superiority of the content of the research proposal
 - (7) Describe the position, originality, novelty, and superiority of this Research proposal in the world, based on the current status and trends of domestic and international research in related fields.

2. Project members

<Japan-based researchers>

Team	Role	Name	Affiliated Institution	Position
Team 1	Principal Investigator			
Team 1	(Sub-Principal Investigator)			
Team 1	(Research Collaborator)			
Team 3	(Sub-Principal Investigator)			
Team 3	(Research Collaborator)			

■ Please specify the members of each team.

■ Please add the number of teams as necessary.

<Swiss-based researchers>

Team	Role	Name	Affiliated Institution	Position
Team 2	Principal Investigator			
Team 2	(Sub-Principal Investigator)			
Team 2	(Research Collaborator)			
Team 4	(Sub-Principal Investigator)			
Team 4	(Research Collaborator)			

- Sub-Principal Investigator (Sub-PI): A researcher who belongs to a university or research institution in Japan and is affiliated with a different institution from the Research PI, and who receives and executes the contract research fund at his/her own institution, or a researcher who belongs to the same institution as the Research PI and plans to proceed with the research as a representative of the Research item to be shared by the Research PI. The researcher who belongs to the same institution as the Research Principal Investigator and plans to conduct research as a representative of the shared Research item.

- Please add more lines if necessary.

3. Implementation system diagram

- Draw an implementation system diagram showing the organizations (in the event that the affiliated institution and the main place of research are different bodies, also provide details of the main place of research) of Principal Institution and Subsidiary Institution(s) in both countries, frameworks, collaboration and cooperation structures, etc. The diagram should clearly show the roles of each item. Also describe the frameworks and methods for Research project administration, promotion and progress management, etc.
- The diagram below has been attached as visual data as an example, so delete it when creating your research proposal and attach below your own system diagram created with an appropriate software tool.

【Example】


Rounded rectangles: Universities etc.

Oval: Companies

Rectangle: AMED/SNSF

Dotted lines: Agreements/contracts

Double arrows: Exchange of samples and information etc./ role sharing



4. Research plan and methods

<Collaborative research plan>

[illegible][illegible][illegible][illegible]

<Annual plan for each research items>

Research Item 1: Research Title <names of participating researchers>

.....
.....,.....
.....,.....
.....,.....
.....,.....
.....,.....
......

Fiscal Year 1:

.....
.....,.....
.....,.....
.....,.....
.....,.....
.....,.....
.....

Fiscal Year 2:

.....
.....,.....
.....,.....
.....,.....

Fiscal Year

.....
.....
.....
.....

- In A4 10 pages, describe the specific research plan and method in order to achieve what is described in 1. Research background and objectives.
- Please clearly describe the specific roles of the “Principal Investigator in Japan,” “Principal Investigator in Switzerland,” “Sub-PI(s),” and “Research Collaborator(s),” and etc., with regard to the research structure to carry out the research plan.
- In the annual plan, please describe in detail who is in charge of each Research item, their roles, the details of implementation for each fiscal year, and research methods. Please add additional Reserach items as necessary.
- In addition, attach the main schedule for Research (roadmap), an implementation system diagram respectively.

Fiscal Year 4:

.....
.....,.....
.....,.....
.....,.....

Fiscal Year 5:

Fiscal Year 6:

Research Item 2: Research Title <names of participating researchers>

Fiscal Year 1:

Fiscal Year 2:

9

Fiscal Year 3:

Fiscal Year 4:

Fiscal Year 5:

Fiscal Year 6:

10

Research Item 3: Research Title <names of participating researchers>

[illegible]

Fiscal Year 1:

Fiscal Year 2:

Fiscal Year 3:

Fiscal Year 4:

Fiscal Year 5:

The diagram illustrates a sequence of 1000 small circles arranged in 10 rows of 100. The circles are colored blue and red, representing a binary sequence. The sequence starts with 100 blue circles, followed by 100 red circles, and then continues with a mix of blue and red circles, ending with 100 blue circles.

Fiscal Year 6:

5. Plan to promote international mobility activities

(1) Plan for building and expanding international network









- Please describe in **one A4 page** a specific plan for building and expanding an international network through this proposal for the purpose of building, participating in, and developing an international top research community.
- Please be sure to include the following.
 - If you are already participating in an international top research community, please describe how you intend to develop the top research community in the future.
 - If you are already participating in an international top research community, please describe how you aim to develop the top research community in the future.

(2) Human resource development plan for next-generation researchers

- Please describe in **one A4 page** a specific plan for fostering researchers who are expected to become the next generation of top researchers.
- The following must be included in the plan for fostering the next generation of researchers.
 - Dispatch of Japanese researchers to Switzerland for a period of at least one year in principle.
 - Invite excellent researchers from Switzerland to Japan.
- The above plan must include the number of participants, period of stay, specific research and exchange plans for travel and invitation, including the destination and the place of invitation, the acceptance system at the destination and the place of invitation, and the expected results.
- Please include a schedule of your plans for promoting international mobility activities in (3).
- Please be sure to include the following
 - How have you fostered young researchers and what results have you achieved so far?
 - Based on the results of fostering young researchers to date, how will the next generation of researchers be fostered through this proposal?

(3) Plan to promote international mobility activities

- Please describe your plan for promoting international mobility activities during the period of the commissioned research and the period or timing of implementation.
- Please enter the name and travel period of the person to be dispatched and the name and invitation period of the inviting. If undecided, please enter “Researcher A”, “Doctoral Student A”, etc.
- Please describe the plan and implementation period or timing of the workshop for personnel and research exchange.

Description	Name・Title	FY1~2	FY3~FY4	FY5~FY6
(1) Dispatch Plan	Researcher A		 	
(2) Invitation Plan	PhD A Postdoctoral Fellow A		 	
(3) Exchange Event		 【City, Date, Year】	 【City, Date, Year】	 【City, Date, Year】

6. Main schedule for research

- Enter the research items that must be dealt with in order to achieve the objectives, as well as the period of execution.
- For each research item, enter the schedule and the persons in charge.
- *The main schedule for research should be one page or less.
- It is acceptable for a diagram separately made with Excel to be attached. Note that when converting to a PDF file, some symbols such as arrows etc. may become misaligned so be sure to check after PDF conversion.

Research Item	Names	1st year (FY2025)	2nd year (FY2026)	3rd year (FY2027)	4th year (FY2028)	5th year (FY2029)	6th year (FY2030)
(1) Analysis of XX related gene manifestation • Identification of XX genes • Analysis of XX gene manifestation <(i), (ii), (iv)>		←→	←→				
(2)			←→	←→			
(3)					←→	←→	
(4)						←→	
(5)							
(6)							

7. Estimated budget and requested funding

- Direct costs must not exceed 115,000 thousand yen for Japan-based applicants. If this amount is exceeded, the application cannot be accepted.
- For Japan-based applicants: After the contract is signed, the amount allocated for each expense item may be diverted between expense items without AMED approval, provided that the amount allocated does not exceed 50% of the total direct expenses for the fiscal year. However, the amount to be diverted must be reasonable and consistent with the research plan.
- Direct costs must not exceed 625'000 CHF for Swiss-based applicants. If this amount is exceeded, the application cannot be accepted.

Team	Type of costs	Budget requested to AMED (Yen)		Budget requested to SNSF (CHF)	
		Mobility	Others	Mobility	Others
Team 1	Costs of goods (equipment/supplies)				
	Travel costs				
	Personnel cost/ Service cost				
	Others				
	Subtotal				
Team 2	Costs of goods (equipment/supplies)				
	Travel costs				
	Personnel cost/ Service cost				
	Others				
	Subtotal				
Team 3 Add as many teams as necessary.	Costs of goods (equipment/supplies)				
	Travel costs				
	Personnel cost/ Service cost				
	Others				
	Subtotal				
Subtotal of all teams		A	B	C	D
Direct Cost (Mobility + Others)		Max.115,000 thousand of yen (A+B)		Max 625'000 CHF (C+D)	
% of Mobility		=Mobility(A)/Direct Cost(A+B) X 100		=Mobility(C)/Direct Cost(C+D) X 100	
Overhead Costs		30% of direct costs for Japan-based applicants (E)		XX% of direct costs for Swiss-based applicants (F)	
Total Budget (Direct + Overhead Costs)		A+B+E		C+D+F	

8. Budgets for building and expanding international networks and promoting international mobility activities to foster the next generation of researchers

- Please specify the total amount of expenses you plan to use for the purpose of building and expanding international networks and fostering next-generation researchers that will contribute to the promotion of international mobility activities.
- International mobility activities include personnel expenses for the next generation of researchers, expenses incurred during travel to the partner country, and expenses incurred after travel (e.g., accommodation, insurance, etc.). International mobility activities also include the costs of organizing workshops and hiring administrative support staff.
- Please agree on the cost-sharing with the counterpart research institution in advance.
- International mobility activity expenses should be planned to be at least 33% of the total direct expenses of both countries.

	Main items	For Japan-based project (Yen)	For Swiss-based project (Yen) ※Calculate at 170 yen per CHF
Mobility cost	Costs of goods (equipment/supplies)		
	Travel costs		
	Personnel cost/ Service cost		
	Others		
	Subtotal	A	C in yen
	Total of the two countries	A+C	
Total budget for each country (Direct cost)		A+B	C+D
Total budget of the two countries (Japan + Swiss)		A+B+C+D	

9. Research achievement

- Paste the links to the ORCID or researchmap pages of the “Principal Investigator”, “Sub-Principal Investigator”, “Partner Country Principal Investigator” and “Partner Country Sub-Principal Investigator”. (If you do not have an ORCID ID or researchmap, please paste a link to the Researcher Information page of Publons or Google Scholar, for example.)
- Please select the main publications (approximately 10 per person) in academic journals for each of the “Principal Investigator(s)”, “Sub-Principal Investigator(s)” and “Counterpart Principal Investigator(s)” and list them in order from the most recent year. Please also mark “●” for papers and publications that are directly related to the proposed project.
- Please specify the Top10% international co-authored papers among the above. Please clearly indicate the database used, how the Top 10% is defined, and evidence that identifies the paper as a Top 10% paper.
- For the three publications related to this proposal, please provide a brief description of what you have clarified in the published papers and the contributions of the proposer to the research, if necessary.
- Please describe keynote speeches at major international conferences in the past 10 years. Please provide sufficient information to identify the relevant research achievements (e.g., name of international conference, location, date, etc.).
- For the three international conferences related to this proposal, please provide a brief description of the contributions and other appealing points of the proposer, if necessary.
- Please describe the results of international personnel exchange (dispatching young researchers, inviting researchers from other countries, holding symposiums, etc.) and the outcomes of such exchange over the past 10 years. When describing achievements, please include specific details such as the number of persons, duration of stay, and location.

(1) Principal Investigator: XX XX

URL: <https://www.>

< Publications and books >

M.Marusankaku, J.Aaaa, H.Bbbbb, A.Ccccc, Treatment of Hepatic....., Nature, 2020 , 1,10-20

M.Marusankaku, T.Aaaa, A.Bbbbb, T.Ccccc, Risk factors for Fungal..., Nature, 2019, 2,17-26

< Top 10% International Co – authored Publications >

M.Marusankaku, J.Aaaa, H.Bbbbb, A.Ccccc, Treatment of Hepatic....., Nature, 2020 , 1,10-20

M.Marusankaku, T.Aaaa, A.Bbbbb, T.Ccccc, Risk factors for Fungal..., Nature, 2019, 2,17-26

DATABASE:

Definition Method:

Points of appeal:

< Keynote Speeches >

M.Marusankaku, J.Aaaa, H.Bbbbb, A.Ccccc, Treatment of Hepatic....., Conference, 2021,Tampa, USA

Points of Appeal:

<International Human Resource Exchange Achievements>

(2) Sub-Principal Investigator: XX XX

URL: <https://www.>

<Publications and books>

M.Marusankaku, J.Aaaa, H.Bbbbb, A.Ccccc, Treatment of Hepatic....., Nature, 2020 , 1,10-20

M.Marusankaku, T.Aaaa, A.Bbbbb, T.Ccccc, Risk factors for Fungal..., Nature, 2019, 2,17-26

<Top 10% International Co - authored Publications>

M.Marusankaku, J.Aaaa, H.Bbbbb, A.Ccccc, Treatment of Hepatic....., Nature, 2020 , 1,10-20

M.Marusankaku, T.Aaaa, A.Bbbbb, T.Ccccc, Risk factors for Fungal..., Nature, 2019, 2,17-26

DATABASE:

Definition Method:

Points of appeal:

<Keynote Speeches>

M.Marusankaku, J.Aaaa, H.Bbbbb, A.Ccccc, Treatment of Hepatic....., Conference, 2021,Tampa, USA

Points of Appeal:

<International Human Resource Exchange Achievements>

10. Information on the Principal Investigator and Sub-Principal Investigator(s)
(Only for Japan-based researchers)

	Name	Affiliated institution ¹	Current professional field	FY 2025 research costs ² (Unit: 1000 yen)	Effort (%)
	Month and year of birth (age as of April 1, 2025)	Department/Division ¹	Degree (final academic background) Year degree acquired		
		Position ¹	Responsibilities within each research project		
Principal Investigator	XX XX	XXXX University	XXX		
	November 1974 (XX)	Department of XXX, Faculty of XXX	Ph. D (XXX) (XX University) 2002	X,XXX	XX
		XXX	Research supervision		
	/	(Main place of research) ¹ XXXX University	/	X,XXX	XX
		Department of XXX, Faculty of XXX			
		XXX			
Sub-Principal Investigator	XX XX	XXXX University	XXX		
	November 1975 (XX)	Department of XXX, Faculty of XXX	Ph. D (XXX) (XX University) 2003	X,XXX	XX
		XXX	Data analysis		
	/	(Main place of research) ¹ XXXX University	/	X,XXX	XX
		Department of XXX, Faculty of XXX			
		XXX			
Sub-Principal Investigator					
Total: 2 people			Total Research costs	X,XXX	

¹ In the event that the affiliated institution and the main place of research are different bodies, also provide the details of the main place of research (research institution, department/division, and position).

² Enter direct costs with regard to research costs

11. Breakdown of costs for each fiscal year (Only for Japan-based researchers)

Please make copies of the table as necessary and clearly indicate the principal and subcontracting organizations, respectively.

(Unit: 1,000 yen)

Main items		Sub items	FY2025	FY2026	FY2027	FY2028	FY2029	FY2030	Total
Direct costs	1. Costs of goods	Equipment costs							
		Consumable item costs							
	2. Travel costs	Travel costs							
	3. Personnel costs/ services costs	Personnel costs*							
		Services costs							
	4. Other	Subcontract costs							
		Other							
	Subtotal								
Indirect costs (In general, 30% of aforementioned direct costs)									
Total									

* If you wish to utilize the System for Improving Research Capability (PI Personnel Costs), please check that the following conditions have been met and enter the items below. (If you do not wish to utilize the system, there is no need to enter these items.)

- (1) The PI himself/herself wishes to allocate (a portion of) the PI personnel costs to direct costs.
- (2) The research institution with which the PI is affiliated has established a system for appropriately executing the financial resources secured for the improvement of research capabilities.
- (3) The research institution with which the PI is affiliated implements personnel and salary management, such as reflecting research performance evaluations in treatment.

What is the System for Improving Research Capability (PI Personnel Costs)?:

https://www.amed.go.jp/keiri/youshiki_itaku.html#i00-01 (in Japanese)

Name of the PI (effort percentage under this research; amount applied for: XX XX (XX%; approximately XX thousand yen/year)

Expected outcome:

The graph shows a green line starting at a low point on the left, rising sharply to a peak near the top of the frame, and then gradually declining as it moves towards the right edge of the slide. The background of the slide features faint, repeating circular patterns.

- The information entered regarding the System for Improving Research Capability (PI Personnel Costs) will also be subject to review.
- If you wish to utilize this system, it is mandatory to enter the relevant information at the time of proposal submission.

12. Status of research application, acceptance and effort (Only for Japan-based researchers)

- Enter (1) the research funds/grants (including and regardless of whether they are from Japan or overseas, and in addition to competitive research funds, grants from private sector foundations, contracted research funds from corporations and research funds such as joint research funds; the same applying hereinafter) currently being applied for, (2) the research funds/grants for which the Principal Investigator of this proposed research project has been selected (funds/grants currently being received and scheduled to be received) and (3) other activities, of the said Principal Investigator at the time of application, giving consideration to the points listed below. When entering multiple funds/grants, draw lines to demarcate the funds/grants.
- In the Effort column, enter the percentage of researcher's time exclusively spent for the research activities concerned against the researcher's annual working hours (100%).
- At the beginning of (1) Research funds/grants currently being applied for, enter this proposed Research project.

(1) Research funds/grants currently being applied for (as of Month Day, Year)

Title of research funding program/ Research funds/grants (research period/ funding agency)	Title of Research project (name of Principal Investigator)	Role (Principal Investigator or Sub-Principal Investigator)	Research costs for FY 2025 (direct costs) [amount for entire period] (Unit: 1000 yen)	Effort (%)	Differences in research content and reason for applying for this Research project being solicited in addition to other research funds/grants
Amount expected be allocated to applicant (direct costs)			The total amount of research project costs (direct costs)		
This proposed Research project (2023–2025)	Experimental research on the correlation between XX and XX (XXXX)	Principal Investigator	6,000 [18,000]	20	(Total amount: 21,000)*
Grants-in-Aid for Scientific Research (KAKENHI)/ Challenging Research (Exploratory) (JSPS, FY2023–FY2024)	Investigative research on the dependence on XX of XX and XX (XXXX)	Principal Investigator	3,000 [9,000]	10	The research is different in that it approaches the study from the perspective of XX, and conducting this research will promote comprehensive understanding. (Total amount: 9,000)*
FY2023 XX Foundation research grant (XX Foundation, 2023)	Research on XX and YY (XXXX)	Sub-Principal Investigator	1,000 [1,000]	5	The research is different in that it approaches the study from the perspective of XX, and conducting this research will promote comprehensive understanding.

(2) Research funds/grants for which the applicant has been selected (funds/grants currently being received and scheduled to be received) (as of Month Day, Year)

(Note: Research funds/grants of which period ends before the fiscal year when this research project commences are not included.)

Title of research funding program/ research funds/grants (research period/ funding agency)	Title of research project (name of Principal Investigator)	Role (Principal Investigator or Sub-Principal Investigator)	Research costs for FY 2025 (direct costs) [amount for entire period](Unit: 1000 yen)	Effort (%)	Differences in research content and reason for applying for this research project being solicited in addition to other research funds/grants
FY 2021 XX Foundation research grant (XX Foundation, 2021)	Research on XX and YY (XXXX)	Principal Investigator	1,000 [1,000]	5	The research is different in that it approaches the study from the perspective of XX, and conducting this research will promote comprehensive understanding. (Total amount: 5,000)*
XX Program (AMED, 2021–2023)	Research on XX and YY (XXXX)	Sub-Principal Investigator	1,000 [5,000]	10	The research is different in that it approaches the study from the perspective of XX, and conducting this research will promote comprehensive understanding.

* In the parentheses (), enter the total direct costs for the entire Research period.

(3) Other activities

Effort: 50 %

Image of “other activities” other than (1) and (2) (organization of thinking)

Education	Effort: 20%
Diagnosis & treatment	Effort: 10%
Social services	Effort: 5%
Others (university administration etc.)	Effort: 15%

13. Past research funds/grants received and resulting achievements (Only for Japan-based researchers)

- In this section, select and describe the portion of the research achievements, etc. made using the research funds/grants received by the Principal Investigator and Sub-Principal Investigator(s) up to now that have been used in the drafting of this research proposal (namely, research funds/grants provided by an affiliated institution, and research funds/grants from an office or ministry, local government, research grant corporation, private sector company etc., including research funds/grants currently being received), dividing them into the research funds/grants for (1) the AMED program and (2) other research funds/grants, with consideration given to the following points.
- Be sure to separately state the achievements between those of the AMED programs and other research funds/grants.
- For each research fund/grant, state the research funding program name, period (fiscal year), research project title, whether it was received as a Principal Investigator or Sub-Principal Investigator, and the research costs (direct costs). In addition, briefly describe also the research achievements and the results of interim and ex post evaluations (Principal Investigators of research funds/grants in question only).

(Items to be recorded)

Name of financing program:

Period (FY): FY ____–FY ____

Name of project:

Principal Investigator or Sub-Principal Investigator:

Research costs (direct costs): _____ (Unit: 1000 yen)

Research achievements and results of interim / ex-post evaluation:

(1) **AMED program**

- AMED XX Program (A), 2015–2017, “Research on XX” Principal Investigator, 40,000 (1000 yen)
Achievements: XXXX
- AMED XX Program (B), 2017–2019, “Research on XX” Principal Investigator, 40,000 (1000 yen)
Achievements: XXXX

(2) **Other research funds/grants**

- Basic research (B), 2014–2016, “Research on XX” Principal Investigator, 40,000 (1000 yen)
Achievements: XXXX

14. Matters requiring special attention in the implementation of the research project (Only for Japan-based researchers)

- Since the matters below are important perspectives in research in the medical field, it is requested that they are described for research projects under AMED programs. Unless otherwise specified as special conditions in the Application Guidelines, they will not affect the selection outcome. Note that the information provided may be utilized to analyze the research trends that will contribute to AMED program management in the future, and its results publicized in a way that the research project in question cannot be identified.

(1) Patient and Public Involvement (PPI) in medical research/clinical studies

* Please refer to the AMED website concerning the points about recording details.

Patient and Public Involvement (PPI) in Research: <https://www.amed.go.jp/en/ppi/guidebook.html>

(2) Ethical Considerations

1. Guidelines related to research to be followed	
<input checked="" type="checkbox"/> Not applicable to the following laws/guidelines <input type="checkbox"/> Clinical Trials Act <input type="checkbox"/> Ministerial Ordinance on Good Clinical Practice for Drugs <input type="checkbox"/> Ministerial Ordinance on Good Clinical Practice for Medical Devices <input type="checkbox"/> Act on Ensuring the Safety of Regenerative Medicine, etc. <input checked="" type="checkbox"/> Act on the Conservation and Sustainable Use of Biological Diversity through Regulations on the Use of Living Modified Organisms <input type="checkbox"/> Ethical Guidelines for Life Sciences and Medical Research Involving Human Subjects <input type="checkbox"/> Guidelines on Clinical Research of Gene Therapy <input type="checkbox"/> Basic Guidelines for Conducting Animal Experiments, etc. in Research Institutions <input type="checkbox"/> Other guidelines (Name of the guideline: _____)	
2. Availability of clinical research planned during the period of this research and development	
<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No If "Yes", please describe the planned contents and the status of passing the Ethics Committee.	
Target disease	Planned content, timing of implementation, and status of passage of ethics committee
△ △ Infectious Disease	Epidemiological study of △ △ △ △, R6 XX to XX XX, Passed through the Ethics Committee at ●● Hospital in XX, RX (No.: IRB-YYYYY)

(3) Keywords (other than diseases, 10 items maximum)

List the keywords that express the proposal content and you consider are appropriate and important. (E.g.: specific names of the following: research methodology, techniques used, drug modality, biological phenomena, target body area (organ, tissue, cell etc.), target groups (pregnant women, AYA generation) etc.), laboratory animals etc.).

1. XX measurements 2. XX Synthetic inhibitor 3.

(4) Target diseases (10 items maximum)

List no more than ten main disease names in ascending order from the closest to the main topic of the research.

In the event that undiagnosed diseases are the target subject, state "undiagnosed disease" and when there is no specific target disease or it has yet to be decided, state "no target disease."

1. [XX infectious disease](#)
2. [XX disease](#)
3. [XX syndrome](#)

(別紙1) 機関長からの承諾書

※日本側のみ

年 月 日

承 諾 書

国立研究開発法人日本医療研究開発機構 御中

(研究開発代表機関)

機関名

機関長名

公印 (省略可)

先端国際共同研究推進プログラムに提案しています、下記の研究開発提案について、採択された場合には、機関として国際共同研究の支援を行うことを確認します。具体的には、以下について機関として執行します。

記

○研究開発課題名 「 」

○研究開発代表者名

- ・相手国側研究機関との国際共同研究の実施に関する合意文書の取り交しの支援
- ・相手国側研究機関との合意文書の内容の遵守及び事業契約の履行ならびに経費の執行管理
- ・共同研究体制を構築する場合の研究代表機関としての責務の遵守
- ・若手研究者育成の一環として大学院生や学部生の海外派遣に関する安全管理及び責任体制の構築
- ・相手国側研究者を研究機関にて受け入れる際の安全管理及び責任体制の構築
- ・その他、国際共同研究を実施するために必要な手続き等の支援
- ・研究実施期間中の研究代表者を中心とした研究体制の確保 (下記内容にも必ずお答えください。)

研究実施期間中に研究開発代表者が 定年等を迎える予定である。	(はい) とお答えになる場合、組織内で研究実施体制を 確保するための方策を明記してください。
(はい / いいえ)	

安全保障貿易管理に係るチェックシート

※日本側のみ

研究開発代表者名：

研究開発課題名：

公募要領の「II-5.1.2 安全保障貿易管理について（海外への技術漏洩への対処）」を参照し、下記1)～4)について確認・記載してください。**なお、本紙の内容は相手国側資金配分機関へ共有する可能性があります、国際共同研究提案の採否には一切影響しません。**

1) 「貨物等省令第2条の2 第1項」について

- CIHRへ提出する提案書本文に、「貨物等省令第2条の2 第1項」における以下の物品に関する研究が含まれているかを確認してください。
- その上で、各項目について「含む」もしくは「含まない」のいずれか該当する方の「□」を「■」に書き換えてください。
- 含む場合には、該当する物品名に下線を引き、提案書中の当該物品の設計、製造(※)に関する記載の有無について該当する方の「□」を「■」に書き換え、記載がある場合は、提案書中の項目番号を記入してください。

※設計とは：一連の製造過程の前段階のすべての段階（設計研究、設計解析、設計概念、プロトタイプの製作及び試験、パイロット生産計画、設計データ、設計データを製品に変化させる過程、外観設計、総合設計、レイアウト等）

製造とは：すべての製造過程（建設、生産エンジニアリング、製品化、統合、組立/アセンブリ、検査、試験、品質保証等）

貨物等省令第2条の2 第1項※

項目	物品名	左記物品に関する研究	提案書中の左記研究に関する設計、製造に関する記載
第一号	ウイルス（ワクチンを除く。）であって、アフリカ馬疫ウイルス、アフリカ豚熱ウイルス、アンデアン・ポテト・ラテント・ウイルス、アンデスウイルス、エボラウイルス属の全てのウイルス、黄熱ウイルス、オムスク出血熱ウイルス、オロポーチウイルス、ガナリトウイルス、キャサヌール森林病ウイルス、牛疫ウイルス、クリミア・コンゴ出血熱ウイルス、口蹄疫ウイルス、高病原性鳥インフルエンザウイルス（H5又はH7のH抗原を有するものに限る。）、SARSコロナウイルス、再構成1918年インフルエンザウイルス、サビアウイルス、サル痘ウイルス、小反芻獣疫ウイルス、シンノブレウイルス、水疱性口内炎ウイルス、西部ウマ脳炎ウイルス、セントルイス脳炎ウイルス、ソウルウイルス、ダニ媒介脳炎ウイルス（極東型に限る。）、チクングニアウイルス、チャパレウイルス、跳躍病ウイルス、テュクロウイルス、痘瘡ウイルス、東部ウマ脳炎ウイルス、ドブラバーベルグレドウイルス、ニパウイルス、日本脳炎ウイルス、ニューカッスル病ウイルス、ハンタンウイルス、豚熱ウイルス、豚水疱病ウイルス、豚テシオウイルス、豚ヘルペスウイルス-1、フニン	<input type="checkbox"/> 含む （→該当する物品に下線を引き、右欄もチェックする） <input type="checkbox"/> 含まない	<input type="checkbox"/> 記載有 （→記載のある項目の番号：_____） <input type="checkbox"/> 記載無

	ウイルス、ブルータングウイルス、ベネズエラウマ脳炎ウイルス、ヘンドラウイルス、ポテト・スピンドル・チュバー・ウィロイド、ポワッサンウイルス、マチュポウイルス、MERSコロナウイルス、マールブルグウイルス属の全てのウイルス、マレー渓谷脳炎ウイルス、ヤギ痘ウイルス、羊痘ウイルス、ラグナネグラウイルス、ラッサウイルス、ランピースキン病ウイルス、リッサウイルス属のウイルス（狂犬病ウイルスを含む。）、リフトバレー熱ウイルス、リンパ球性脈絡髄膜炎ウイルス、ルヨウイルス又はロシオウイルス		
第二号	細菌（ワクチンを除く。）であって、アルゲンチネンス菌（ボツリヌス神経毒素産生株に限る。）、ウェルシュ菌（イプシロン毒素産生型のものに限る。）、ウシ流産菌、オウム病クラミジア、牛肺疫菌（小コロニー型）、コクシエラ属バーネッティイ、コレラ菌、志賀赤痢菌、炭疽菌、チフス菌、腸管出血性大腸菌（血清型O26、O45、O103、O104、O111、O121、O145及びO157）、発疹チフスリケッチア、バラチ菌（ボツリヌス神経毒素産生株に限る。）、鼻疽菌、ブタ流産菌、ブチリカム菌（ボツリヌス神経毒素産生株に限る。）、ペスト菌、ボツリヌス菌、マルタ熱菌、山羊伝染性胸膜肺炎菌F38株、野兔病菌又は類鼻疽菌	<input type="checkbox"/> 含む （→該当する物品に下線を引き、右欄もチェックする） <input type="checkbox"/> 含まない	<input type="checkbox"/> 記載有 （→記載のある項目の番号：_____） <input type="checkbox"/> 記載無
第三号、第四号	毒素（免疫毒素を除く。）であって、アフラトキシン、アブリン、ウェルシュ菌毒素（アルファ、ベータ1、ベータ2、イプシロン又はイオタの毒素に限る。）、HT-2トキシン、黄色ブドウ球菌毒素（腸管毒素、アルファ毒素及び毒素性ショック症候群毒素）、ゴニオトキシン、コノトキシン、ジアセトキシスシルペノール、志賀毒素、T-2トキシン、テトロドトキシン、ノジュラリン、パリトキシン、ビスカミン、プレベトキシン、ボツリヌス毒素、ボルケンシン、ミクロシスチン又はモデシン、およびそのサブユニット	<input type="checkbox"/> 含む （→該当する物品に下線を引き、右欄もチェックする） <input type="checkbox"/> 含まない	<input type="checkbox"/> 記載有 （→記載のある項目の番号：_____） <input type="checkbox"/> 記載無
第五号	細菌又は菌類であって、クラビバクター・ミシガネンシス亜種セペドニカス、コクシジオイデス・イミチス、コクシジオイデス・ポサダシ、コレトリウム・カーハワイ、ザントモナス・アルビリネアンス、ザントモナス・オリゼ・パソバー・オリゼ、ザントモナス・シトリ・パソバー・シトリ、シンキトリウム・エンドピオチウム、スクレロフトラ・ライシアエ・バラエティー・ゼアエ、セカフォラ・ソラニ、チレチア・インディカ、バイポラリス・オリゼ、プクシニア・グラミニス亜種グラミニス・バラエティー・グラミニス、プクシニア・ストリイフォルミス、プセウドセルコスボラ・ウレイ、ペロノスクレロスボラ・フィリピネンシス、マグナポルテ・オリゼ又はラルストニア・ソラナセアルム・レース3及び次亜種2	<input type="checkbox"/> 含む （→該当する物品に下線を引き、右欄もチェックする） <input type="checkbox"/> 含まない	<input type="checkbox"/> 記載有 （→記載のある項目の番号：_____） <input type="checkbox"/> 記載無
第六号	遺伝子を改変した生物（意図的な分子操作によって核酸の塩基配列を生成し、又は改変されたものを含む。）であって次のいずれかを有するもの又は遺伝要素（染色体、ゲノム、プラスミド、トランスポゾン、ベクター及び復元可能な核酸断片を含む不活性化された組織体を含む。）であって次のいずれかの塩基配列を有するもの イ 第一号に該当するものの遺伝子又はこれを翻訳した生	<input type="checkbox"/> 含む （→該当する物品に下線を引き、右欄もチェックする） <input type="checkbox"/> 含まない	<input type="checkbox"/> 記載有 （→記載のある項目の番号：_____） <input type="checkbox"/> 記載無

	<p>産物</p> <p>ロ 第二号又は前号に該当するものの遺伝子のうち、人、動物若しくは植物の健康に重大な危害を与えるもの（これを転写し又は翻訳した生産物を通じて危害を与えるものを含む。）又は病原性を付与し若しくは増強することができるもの（血清型〇二六、〇四五、〇一〇三、〇一〇四、〇一一一、〇一二一、〇一四五、〇一五七その他の志賀毒素を産生する血清型をもつ大腸菌の核酸の塩基配列（志賀毒素又はそのサブユニットの遺伝要素を持つものに限る。）を有するもの以外のものを除く。）</p> <p>ハ 第三号又は第四号に該当するもの</p>		
--	--	--	--

※物品の詳細等については、経済産業省HPの安全保障貿易管理 (<https://www.meti.go.jp/policy/anpo/>) を参照すること。

2)「貨物等省令第2条の2 第2項」について

- 提案書に、「貨物等省令第2条の2 第2項」における以下の物品に関する研究が含まれているかを確認してください。
- その上で、各項目について「含む」もしくは「含まない」のいずれか該当する方の「□」を「■」に書き換えてください。
- 含む場合には、提案書中の当該物品の設計、製造、使用（※）に関する記載の有無について該当する方の「□」を「■」に書き換え、記載がある場合は、提案書中の項目番号を記入してください。

※設計とは：一連の製造過程の前段階のすべての段階（設計研究、設計解析、設計概念、プロトタイプの製作及び試験、パイロット生産計画、設計データ、設計データを製品に変化させる過程、外観設計、総合設計、レイアウト等）

製造とは：すべての製造過程（建設、生産エンジニアリング、製品化、統合、組立/アセンブリ、検査、試験、品質保証等）

使用とは：設計、製造以外の段階（操作、据付、保守（点検）、修理、オーバーホール、分解修理等）

貨物等省令第2条の2 第2項（抜粋）※

項目	物品名	左記物品に関する研究	提案書中の左記研究に関する設計、製造、使用に関する記載
第二号	<p>発酵槽又はその部分品であって、次のいずれかに該当するもの</p> <p>イ 使い捨て式以外の発酵槽又はその部分品であって、次のいずれかに該当するもの</p> <p>（一）内容積が20リットル以上の密閉式の発酵槽であって、定置した状態で内部の滅菌又は殺菌ができるもの</p> <p>（二）（一）に該当する発酵槽に用いるように設計された培養容器であって、定置した状態で内部の滅菌又は殺菌ができるもの</p> <p>（三）（一）に該当する発酵槽に用いるように設計された制御装置であって、発酵装置を制御するための2以上のパラメーターを同時に監視及び制御をすることができるもの</p> <p>ロ 使い捨て式の発酵槽又はその部分品であって、次のいずれかに該当するもの</p> <p>（一）内容積が20リットル以上の密閉式の発酵槽</p> <p>（二）（一）に該当する発酵槽に用いるように設計された使い捨て培養容器の収容装置</p> <p>（三）（一）に該当する発酵槽に用いるように設計された制御装置であって、発酵装置を制御するための2以上のパラメーターを同時に監視及び制御をすることができるもの</p>	<p><input type="checkbox"/>含む （→右欄もチェックする）</p> <p><input type="checkbox"/>含まない</p>	<p><input type="checkbox"/>記載有 （→記載のある項目の番号：_____）</p> <p><input type="checkbox"/>記載無</p>
第七号	<p>粒子状物質の吸入の試験に用いるように設計された装置であって、次のいずれかに該当するもの</p> <p>イ 動物の全身を暴露することができる吸入室を有するものであって、吸入室の容積が1立方メートル以上のもの</p> <p>ロ 12以上のげっ歯類の動物又は2以上のげっ歯類以外の動物の鼻部を直接エアゾールを流動させて暴露することができるものであって、これに用いるように設計した動物を保定する密閉型のホルダーを有するもの</p>	<p><input type="checkbox"/>含む （→右欄もチェックする）</p> <p><input type="checkbox"/>含まない</p>	<p><input type="checkbox"/>記載有 （→記載のある項目の番号：_____）</p> <p><input type="checkbox"/>記載無</p>
第九号	核酸の合成又は核酸と核酸との結合を行うための装置であ	<input type="checkbox"/> 含む	<input type="checkbox"/> 記載有

	って、一部又は全部が自動化されたもののうち、一回の稼働で、連続した長さが一・五キロベースを超える核酸を五パーセント未満のエラー率で生成するように設計したもの	(→右欄もチェックする) <input type="checkbox"/> 含まない	(→記載のある項目の番号：_____) <input type="checkbox"/> 記載無
--	--	---	---

※物品の詳細等については、経済産業省HPの安全保障貿易管理 (<https://www.meti.go.jp/policy/ampo/>) を参照すること。

3)「輸出令第1項(14)」について

- 提案書に、「輸出令第1項(14)」における以下の物品に関する研究が含まれているかを確認してください。
- その上で、各項目について「含む」もしくは「含まない」のいずれか該当する方の「□」を「■」に書き換えてください。
- 含む場合には、提案書中の当該物品の設計、製造、使用(※)に関する記載の有無について該当する方の「□」を「■」に書き換え、記載がある場合は、提案書中の項目番号を記入してください。

※設計とは：一連の製造過程の前段階のすべての段階（設計研究、設計解析、設計概念、プロトタイプの製作及び試験、パイロット生産計画、設計データ、設計データを製品に変化させる過程、外観設計、総合設計、レイアウト等）

製造とは：すべての製造過程（建設、生産エンジニアリング、製品化、統合、組立/アセンブリ、検査、試験、品質保証等）

使用とは：設計、製造以外の段階（操作、据付、保守（点検）、修理、オーバーホール、分解修理等）

輸出令第1項(14) ※

項目	物品名	左記物品に関する研究	提案書中の左記研究に関する設計、製造、使用に関する記載
一	<p>軍用の化学製剤の探知若しくは識別のための生体高分子若しくはその製造に用いる細胞株又は軍用の化学製剤の浄化若しくは分解のための生体触媒若しくはその製造に必要な遺伝情報を含んでいるベクター、ウイルス若しくは細胞株</p> <p>生体高分子：以下のいずれかに該当するものをいう。 イ 酵素 ロ モノクローナル抗体、ポリクローナル抗体、抗イデオタイプ抗体 ハ レセプター</p> <p>生体触媒：生体化合物のうち特定の物質に結合し、分解を促進するものであって、人為的な選択又は遺伝子操作を経て生産されたものをいう。</p> <p>ベクター：遺伝物質を親細胞に組み込む媒介体をいう。</p>	<p>□含む (→右欄もチェックする)</p> <p>□含まない</p>	<p>□記載有 (→記載のある項目の番号：_____)</p> <p>□記載無</p>

※物品の詳細等については、経済産業省HPの安全保障貿易管理 (<https://www.meti.go.jp/policy/anpo/>) を参照すること。

4) その他の技術について

- 提案書に、外国為替令別表（前述の1）～3）で確認した項目と、第16項を除く。）に該当するような技術（※）に関する記載があるかを確認し、該当する方の「□」を「■」に書き換えてください。
- 記載がある場合には、その該当箇所、該当していると考えられる理由、技術の内容等、該当する外国為替令別表の項番・項目、該当する貨物等省令の項番・項目を記載してください。

※外国為替令別表の詳細（貨物・技術のマトリクス表を参照）については、経済産業省 HP から確認してください。（https://www.meti.go.jp/policy/anpo/matrix_intro.html）

※技術とは：貨物の設計、製造又は使用に必要な特定の情報を指す。

設計とは：一連の製造過程の前段階のすべての段階（設計研究、設計解析、設計概念、プロトタイプの製作及び試験、パイロット生産計画、設計データ、設計データを製品に変化させる過程、外観設計、総合設計、レイアウト等）

製造とは：すべての製造過程（建設、生産エンジニアリング、製品化、統合、組立/アセンブリ、検査、試験、品質保証等）

使用とは：設計、製造以外の段階（操作、据付、保守（点検）、修理、オーバーホール、分解修理等）

提案書類について：

研究開発提案書中に、外国為替令別表（前述の1）～3）で確認した項目と、第16項を除く。）に該当するような技術に関する記載があるか。	<input type="checkbox"/> ある <input type="checkbox"/> ない
---	---

技術に関する記載がある場合、下記も記入：

提案書中の 該当箇所	該当していると考えられる理由、技術の内容等	外国為替令別表の該当部分		貨物等省令の該当部分	
		項番	項目	項番	項目